News – Page 12 – Anthydoc

Wilmington PharmaTech, on mission to boost US drug ingredient capacity, snares investment from PE firm Curewell

Private equity firm Curewell Capital is aiming to close the gap in U.S. API production with a majority investment in specialty CDMO Wilmington PharmaTech.

October 21, 2025

News·Solutions

India’s ACG pumps $200M into its first US empty-capsule production facility

ACG, a supplier for solid dose drug manufacturers, is pumping $200 million into what will be the India-based company’s first empty-capsule production facility in the U.S.

October 21, 2025

News·Solutions

Merck grows again in Va. with $3B small-molecule drug plant, part of planned $70B US outlay

The investment is part of the New Jersey company’s plan to spend more than $70 billion on manufacturing, R&D and capital projects in the U.S. starting this year.

October 20, 2025

News·Solutions

AstraZeneca to spend $445M to boost production of Lokelma at Texas plant

With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia treatment with a $445 million injection of funds. The investment will increase the capabilities of AZ’s

October 15, 2025

News·Solutions

Particle Dynamics melds with former EuroAPI plant to debut new CDMO Codis

In addition to substantial spray drying capacity, new CDMO Codis says it’s also equipped to handle commercial-scale work on amorphous solid dispersions, particle engineering and finished dose manufacturing for pharma, consumer health

October 15, 2025

News·Solutions

BioNTech’s African mRNA vaccine production push gets EU funding boost

As BioNTech works to establish a production footprint for mRNA vaccines in Africa, two EU groups have offered financial backing to the company’s efforts.

October 14, 2025

News·Solutions

Novo plant hit with FDA’s most serious inspection classification, portending possible delays for partners

The FDA has tagged Novo Nordisk’s newly acquired manufacturing facility in Indiana with an official action indicated label, which is the most severe of the three inspection classifications issued by the agency.

October 13, 2025

News·Solutions

Syngene: Transforming Monoclonal Antibody Manufacturing for the Next Wave of Biologics

October 13, 2025

News·Solutions

Sunrise Labs Rebrands as Suntra MedTech Solutions™

Press Release: MTI Staff was not involved in writing this content October 1, 2025 — Bedford, New Hampshire For over three decades, Sunrise Labs stood at the forefront of engineering excellence and

October 13, 2025

News·Solutions

German drug delivery specialist LTS grows US footprint with buyout of CDMO Renaissance Lakewood

Germany’s LTS—whose bread-and-butter business revolves around developing and manufacturing drug delivery systems—is paying an undisclosed sum to purchase U.S. CDMO Renaissance Lakewood, which itself specializes in nasals sprays and sterile dosage forms.

October 13, 2025

News·Solutions

News - Page 12